Showing results (131-140 of 195) with videos related to
Sort By:
Pageof 20
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 16, 2002
A multicentre, randomised phase III trial comparing protracted venous infusion (PVI) 5-fluorouracil (5-FU) with PVI 5-FU plus mitomycin C in patients with inoperable oesophago-gastric cancerN C Tebbutt, A Norman, D Cunningham, et al.Cancer Treatment Reports|October 1, 1980
Danazol treatment of advanced breast cancerR C Coombes, D Dearnaley, J Humphreys, et al.Clinical Oncology (Royal College of Radiologists (Great Britain))|January 1, 1996
Factors affecting acute skin toxicity in patients having breast irradiation after conservative surgery: a prospective study of treatment practice at the Royal Marsden HospitalI N Fernando, H T Ford, T J Powles, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 26, 2000
Prediction of clinical outcome from primary tamoxifen by expression of biologic markers in breast cancer patientsJ Chang, T J Powles, D C Allred, et al.British Journal of Cancer|February 1, 1996
Phase II study of continuous infusional 5-fluorouracil with epirubicin and carboplatin (instead of cisplatin) in patients with metastatic/locally advanced breast cancer (infusional ECarboF): a very active and well-tolerated outpatient regimenH Bonnefoi, I E Smith, M E O'Brien, et al.Lancet (London, England)|January 15, 1977
Biochemical markers in human breast cancerR C Coombes, T J Powles, J C Gazet, et al.British Medical Journal|July 15, 1978
Failure to detect intra-abdominal metastases from breast cancer: a case for staging laparotomyJ M Thomas, W H Redding, R C Coombes, et al.Cancer Chemotherapy and Pharmacology|January 1, 1987
Oral 4-hydroxyandrostenedione, a new endocrine treatment for disseminated breast cancerD Cunningham, T J Powles, M Dowsett, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 17, 2002
Prospective randomized trial comparing mitomycin, cisplatin, and protracted venous-infusion fluorouracil (PVI 5-FU) With epirubicin, cisplatin, and PVI 5-FU in advanced esophagogastric cancerP Ross, M Nicolson, D Cunningham, et al.Breast Cancer Research and Treatment|April 17, 1999
Quantitative changes in cytological molecular markers during primary medical treatment of breast cancer: a pilot studyA Makris, T J Powles, D C Allred, et al.Pageof 20